UBS AM
TERN

UBS AM’s Terns Pharmaceuticals TERN Stock Holding History

UBS AM’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Buy
94,646
+94,028
+15,215% +$3.86M ﹤0.01% 1557
2025
Q4 		$25K Buy
+618
New +$14.3K ﹤0.01% 2707
2024
Q2 		– Sell
-17,870
Closed -$117K – 2878
2024
Q1 		$117K Hold
17,870
– – ﹤0.01% 2491
2023
Q4 		$116K Buy
+17,870
New +$94.5K ﹤0.01% 2522

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

UBS AM's TERN Position: Q1 2026 in Review

UBS AM increased its Terns Pharmaceuticals (TERN) stake by 15,215% in Q1 2026, buying an estimated $3.86M and bringing the position to 94,646 shares worth $4.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

UBS AM first reported a position in TERN in Q4 2023 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • UBS AM held 94,646 shares of Terns Pharmaceuticals worth $4.99M as of Q1 2026.
  • UBS AM bought 94,028 Terns Pharmaceuticals shares in Q1 2026, an estimated $3.86M.
  • Terns Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1557 holding.
  • UBS AM first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.